Reuben Saba, PhD.

Vice President, Scientific and Medical Affairs

Dr. Reuben Saba is the Vice President of Scientific and Medical Affairs for Medicure Inc. and directs, manages and coordinates all activities within these departments. At Medicure, Dr. Saba was involved in commercial launch of the High Dose Bolus (HDB) Regimen of Aggrastat® (tirofiban hydrochloride) injection in 2014, Zypitamag™ (pitvastatin) in 2018 and Remote Dielectric Sensing (ReDS™) Technology in 2019. Dr. Saba began his tenure at Medicure as a Medical Science Liaison in the U.S. Midwest Regions and soon became the Regional Medical Affairs Manager in 2015 for the US Midwest and Northeast regions. Dr. Saba became the Director of Medical Affairs, Medical Information and Medical-Technical Marketing in 2019 prior to accepting his current role. Before joining Medicure Inc., Dr. Saba worked at the Public Health Agency of Canada (PHAC) in the Molecular Pathobiology Department focusing on the host genetics involved in prion pathobiology. Dr. Saba obtained his MSc and PhD at the University of Manitoba and completed post-doctoral training at the Interdisciplinary Center for Neurosciences (IZN) at the University of Heidelberg (Heidelberg, Germany). At IZN, Dr Saba's focus was on the neurobiology of addiction. Dr. Saba is well published and was a recipient of several merit-based fellowships.

Unite Interactive